Catalyst Pharmaceuticals (NASDAQ:CPRX) & AleAnna (NASDAQ:ANNA) Critical Contrast

AleAnna (NASDAQ:ANNA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Volatility and Risk

AleAnna has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Profitability

This table compares AleAnna and Catalyst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AleAnna	-46.01%	-14.90%	-8.74%
Catalyst Pharmaceuticals	36.39%	36.47%	31.85%

Earnings & Valuation

This table compares AleAnna and Catalyst Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AleAnna	$1.42 million	191.97	-$12.34 million	$0.04	102.25
Catalyst Pharmaceuticals	$588.99 million	5.03	$214.33 million	$1.69	14.34

Catalyst Pharmaceuticals has higher revenue and earnings than AleAnna. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AleAnna and Catalyst Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AleAnna	1	0	0	0	1.00
Catalyst Pharmaceuticals	0	0	3	2	3.40

Catalyst Pharmaceuticals has a consensus target price of $34.00, suggesting a potential upside of 40.26%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than AleAnna.

Insider and Institutional Ownership

38.1% of AleAnna shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 42.9% of AleAnna shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats AleAnna on 12 of the 15 factors compared between the two stocks.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.